申联生物(688098) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥89,049,518.25, representing a year-on-year increase of 7.48%[2] - The net profit attributable to shareholders decreased by 15.7% to ¥23,928,559.11, while the net profit after deducting non-recurring gains and losses fell by 18.85% to ¥20,331,229.47[2] - Basic earnings per share were ¥0.06, down 14.29%, and diluted earnings per share were ¥0.05, down 28.57%[2] - Net profit for Q1 2022 was CNY 23,924,876.69, a decrease of 14.7% from CNY 27,985,577.40 in Q1 2021[18] - Earnings per share for Q1 2022 were CNY 0.06, down from CNY 0.07 in Q1 2021[18] Cash Flow - The net cash flow from operating activities was negative at -¥42,272,933.50, a decrease of 2.68% compared to the previous year[2] - In Q1 2022, the cash inflow from operating activities was $21,306,501.49, a decrease of 48.6% compared to $41,439,597.04 in Q1 2021[22] - The company reported a total cash inflow from operating activities of $21,017,968.10 in Q1 2022, which is a 48.5% decrease from $40,795,871.00 in Q1 2021[22] - The cash inflow from financing activities was $61,952.05, down 69.8% from $205,406.68 in Q1 2021[23] - The net cash flow from financing activities was $26,450.05, compared to $205,406.68 in the same quarter last year, indicating a significant decline[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,614,325,906.33, reflecting a slight increase of 0.99% from the end of the previous year[2] - Total current assets as of March 31, 2022, amounted to ¥738,843,284.22, a slight increase from ¥733,461,060.55 at the end of 2021[12] - Total liabilities for Q1 2022 were CNY 115,003,809.35, down from CNY 125,476,791.81 in Q1 2021[14] - The company’s total equity as of Q1 2022 was CNY 1,499,322,096.98, an increase from CNY 1,472,987,526.40 in Q1 2021[14] Research and Development - R&D investment totaled ¥10,181,801.73, a decrease of 27.95%, accounting for 11.43% of operating revenue, down 5.63 percentage points[2] - Research and development expenses for Q1 2022 were CNY 5,196,621.48, compared to CNY 4,904,462.76 in Q1 2021, reflecting a growth of 5.9%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period was 11,086[8] - The largest shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of total shares[8] - The second largest shareholder, UNITED BIOMEDICAL, INC., holds 49,819,210 shares, representing 12.13% of total shares, with 1,815 shares frozen[8] - The company reported a total of 35.82% shareholding by the top four shareholders, indicating significant ownership concentration[9] Other Financial Information - The company reported non-recurring gains of ¥3,597,329.64, with government subsidies contributing ¥277,616.16 and investment income from entrusted management amounting to ¥2,489,808.51[5] - The company experienced a 421.65% increase in fair value gains from trading financial assets[6] - The financial statements for the first quarter of 2022 were not audited[10] - The impact of exchange rate changes on cash and cash equivalents was a negative $8.33 in Q1 2022, contrasting with a positive $14.08 in Q1 2021[23]